Elixir Medical wins FDA breakthrough designation for DynamX BTK implant

Elixir Medical’s DynamX [Image courtesy of Elixir Medical] Elixir Medical today announced it received FDA breakthrough device designation for its DynamX BTK system for treating chronic limb-threatening ischemia. The Milpitas, California-based company designed the adaptive implant to treat narrowed or blocked vessels below the knee (BTK) in patients with chronic limb-threatening ischemia (CLTI). Elixir Medical said the DynamX Bioadaptor metallic device supports the vessel during the healing phase, unlocking and uncaging the vessel while providing essential dynamic support to restore vessel function and maintain an open lumen. “The Bioadaptor platform was developed to transform treatment of coronary and peripheral artery disease,” CEO Motasim Sirhan said in a news release. “We appreciate the FDA recognition of our innovation for treating the CLTI population with BTK disease and its potential impact on the patients suffering from vascular disease.” According to the co…
Read more
  • 0